← Today in NEWSDASH.LIVE
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
2 outlets
·
Stocks
How each outlet headlined it
CNBC
left
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
The Wall Street Journal
right
Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound and Foundayo will be available at a cost of $50 a month. on.wsj.com/4yZWCtN